nodes	percent_of_prediction	percent_of_DWPC	metapath
Imiquimod—CYP3A4—Everolimus—kidney cancer	0.0938	0.201	CbGbCtD
Imiquimod—CYP1A2—Pazopanib—kidney cancer	0.0635	0.136	CbGbCtD
Imiquimod—CYP3A4—Temsirolimus—kidney cancer	0.0634	0.136	CbGbCtD
Imiquimod—CYP1A2—Erlotinib—kidney cancer	0.0453	0.0972	CbGbCtD
Imiquimod—CYP1A2—Sorafenib—kidney cancer	0.0369	0.0791	CbGbCtD
Imiquimod—CYP3A4—Pazopanib—kidney cancer	0.0333	0.0714	CbGbCtD
Imiquimod—CYP3A4—Erlotinib—kidney cancer	0.0238	0.0509	CbGbCtD
Imiquimod—CYP3A4—Paclitaxel—kidney cancer	0.0217	0.0466	CbGbCtD
Imiquimod—CYP3A4—Sorafenib—kidney cancer	0.0193	0.0414	CbGbCtD
Imiquimod—CYP3A4—Vinblastine—kidney cancer	0.0191	0.0409	CbGbCtD
Imiquimod—CYP3A4—Vincristine—kidney cancer	0.0187	0.0402	CbGbCtD
Imiquimod—CYP3A4—Sunitinib—kidney cancer	0.0156	0.0336	CbGbCtD
Imiquimod—CYP3A4—Doxorubicin—kidney cancer	0.0117	0.0251	CbGbCtD
Imiquimod—TLR8—Regulation of toll-like receptor signaling pathway—PIK3CA—kidney cancer	0.000372	0.0031	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CARD11—kidney cancer	0.000371	0.00309	CbGpPWpGaD
Imiquimod—CYP1A2—Xenobiotics—CYP1A1—kidney cancer	0.000367	0.00305	CbGpPWpGaD
Imiquimod—TLR7—Toll-like Receptor Signaling Pathway—PIK3CA—kidney cancer	0.000362	0.00301	CbGpPWpGaD
Imiquimod—TLR7—Immune System—TCEB1—kidney cancer	0.000356	0.00296	CbGpPWpGaD
Imiquimod—TLR7—Immune System—TCEB2—kidney cancer	0.000356	0.00296	CbGpPWpGaD
Imiquimod—CYP1A2—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000352	0.00294	CbGpPWpGaD
Imiquimod—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.00035	0.00292	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000348	0.0029	CbGpPWpGaD
Imiquimod—TLR8—Immune System—ITPR2—kidney cancer	0.000345	0.00287	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—MAPK3—kidney cancer	0.000342	0.00285	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KEAP1—kidney cancer	0.00034	0.00283	CbGpPWpGaD
Imiquimod—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000338	0.00282	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—MAPK3—kidney cancer	0.000338	0.00282	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—PAK1—kidney cancer	0.000338	0.00281	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—ACY1—kidney cancer	0.000337	0.00281	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IFNA1—kidney cancer	0.000329	0.00274	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—MAPK1—kidney cancer	0.000325	0.00271	CbGpPWpGaD
Imiquimod—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000325	0.00271	CbGpPWpGaD
Imiquimod—TLR7—Toll-Like Receptors Cascades—MAPK1—kidney cancer	0.000322	0.00268	CbGpPWpGaD
Imiquimod—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000308	0.00256	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CASP2—kidney cancer	0.000307	0.00256	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—IFNA2—kidney cancer	0.000307	0.00255	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CTSB—kidney cancer	0.000299	0.00249	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CTSD—kidney cancer	0.000298	0.00248	CbGpPWpGaD
Imiquimod—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000295	0.00246	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD34—kidney cancer	0.000295	0.00246	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—TSC2—kidney cancer	0.000289	0.00241	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PSMD7—kidney cancer	0.000289	0.00241	CbGpPWpGaD
Imiquimod—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000283	0.00236	CbGpPWpGaD
Imiquimod—TLR7—Regulation of toll-like receptor signaling pathway—PIK3CA—kidney cancer	0.000282	0.00235	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CARD11—kidney cancer	0.000281	0.00234	CbGpPWpGaD
Imiquimod—CYP1A2—Estrogen Receptor Pathway—JUN—kidney cancer	0.000277	0.00231	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS1—kidney cancer	0.000273	0.00228	CbGpPWpGaD
Imiquimod—CYP1A2—Melatonin metabolism and effects—CYP1A1—kidney cancer	0.000272	0.00227	CbGpPWpGaD
Imiquimod—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000272	0.00227	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000268	0.00224	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ITPR2—kidney cancer	0.000261	0.00218	CbGpPWpGaD
Imiquimod—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000261	0.00217	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.00026	0.00217	CbGpPWpGaD
Imiquimod—TLR8—Immune System—PAK1—kidney cancer	0.000259	0.00216	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUNB—kidney cancer	0.000257	0.00214	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—KIT—kidney cancer	0.000255	0.00213	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNA1—kidney cancer	0.000253	0.00211	CbGpPWpGaD
Imiquimod—TLR8—Immune System—EGR1—kidney cancer	0.000243	0.00202	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IFNA2—kidney cancer	0.000236	0.00196	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CTSB—kidney cancer	0.000227	0.00189	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CTSD—kidney cancer	0.000226	0.00188	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—TSC2—kidney cancer	0.000219	0.00183	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PSMD7—kidney cancer	0.000219	0.00182	CbGpPWpGaD
Imiquimod—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	0.000211	0.00176	CbGpPWpGaD
Imiquimod—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	0.000201	0.00168	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—RAF1—kidney cancer	0.0002	0.00167	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—RELA—kidney cancer	0.0002	0.00166	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—ERBB2—kidney cancer	0.000198	0.00165	CbGpPWpGaD
Imiquimod—TLR8—Immune System—CD8A—kidney cancer	0.000198	0.00165	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PAK1—kidney cancer	0.000197	0.00164	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—MTOR—kidney cancer	0.000196	0.00163	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CD4—kidney cancer	0.000195	0.00163	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KIT—kidney cancer	0.000194	0.00161	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNA1—kidney cancer	0.000192	0.0016	CbGpPWpGaD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000191	0.0016	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—kidney cancer	0.000188	0.00157	CbGpPWpGaD
Imiquimod—CYP1A2—Tryptophan metabolism—CYP1A1—kidney cancer	0.000188	0.00157	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—kidney cancer	0.000188	0.00157	CbGpPWpGaD
Imiquimod—CYP1A2—Phase II conjugation—GSTT1—kidney cancer	0.000186	0.00155	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—ALDH1A1—kidney cancer	0.000185	0.00154	CbGpPWpGaD
Imiquimod—TLR7—Immune System—EGR1—kidney cancer	0.000184	0.00153	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CDKN1B—kidney cancer	0.000184	0.00153	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IFNA2—kidney cancer	0.000179	0.00149	CbGpPWpGaD
Imiquimod—CYP1A2—Arachidonic acid metabolism—CYP1A1—kidney cancer	0.000176	0.00147	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—JUN—kidney cancer	0.000175	0.00146	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—CTNNB1—kidney cancer	0.000173	0.00145	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—PTEN—kidney cancer	0.000169	0.00141	CbGpPWpGaD
Imiquimod—TLR8—Immune System—TSC2—kidney cancer	0.000168	0.0014	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000152	0.00127	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—RAF1—kidney cancer	0.000152	0.00127	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—RELA—kidney cancer	0.000151	0.00126	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—ERBB2—kidney cancer	0.00015	0.00125	CbGpPWpGaD
Imiquimod—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.00015	0.00125	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD8A—kidney cancer	0.00015	0.00125	CbGpPWpGaD
Imiquimod—TLR8—Immune System—KIT—kidney cancer	0.000149	0.00124	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MTOR—kidney cancer	0.000148	0.00124	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—CD4—kidney cancer	0.000148	0.00123	CbGpPWpGaD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000148	0.00123	CbGpPWpGaD
Imiquimod—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.000145	0.00121	CbGpPWpGaD
Imiquimod—TLR8—Innate Immune System—MAPK3—kidney cancer	0.000144	0.0012	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000143	0.00119	CbGpPWpGaD
Imiquimod—Palpitations—Paclitaxel—kidney cancer	0.00014	0.000337	CcSEcCtD
Imiquimod—Insomnia—Gemcitabine—kidney cancer	0.000139	0.000336	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CDKN1B—kidney cancer	0.000139	0.00116	CbGpPWpGaD
Imiquimod—Eye disorder—Capecitabine—kidney cancer	0.000139	0.000336	CcSEcCtD
Imiquimod—Headache—Erlotinib—kidney cancer	0.000139	0.000335	CcSEcCtD
Imiquimod—Tinnitus—Capecitabine—kidney cancer	0.000139	0.000335	CcSEcCtD
Imiquimod—Loss of consciousness—Paclitaxel—kidney cancer	0.000139	0.000335	CcSEcCtD
Imiquimod—Pain—Vincristine—kidney cancer	0.000139	0.000335	CcSEcCtD
Imiquimod—Pain in extremity—Doxorubicin—kidney cancer	0.000139	0.000335	CcSEcCtD
Imiquimod—Paraesthesia—Gemcitabine—kidney cancer	0.000138	0.000334	CcSEcCtD
Imiquimod—Flushing—Capecitabine—kidney cancer	0.000138	0.000334	CcSEcCtD
Imiquimod—Cough—Paclitaxel—kidney cancer	0.000138	0.000333	CcSEcCtD
Imiquimod—Asthenia—Sunitinib—kidney cancer	0.000138	0.000332	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—MAPK1—kidney cancer	0.000137	0.00115	CbGpPWpGaD
Imiquimod—Dyspnoea—Gemcitabine—kidney cancer	0.000137	0.000331	CcSEcCtD
Imiquimod—Nausea—Vinblastine—kidney cancer	0.000137	0.000331	CcSEcCtD
Imiquimod—TLR8—Immune System—CDH1—kidney cancer	0.000137	0.00114	CbGpPWpGaD
Imiquimod—Somnolence—Gemcitabine—kidney cancer	0.000137	0.000331	CcSEcCtD
Imiquimod—Convulsion—Paclitaxel—kidney cancer	0.000137	0.00033	CcSEcCtD
Imiquimod—Migraine—Doxorubicin—kidney cancer	0.000136	0.00033	CcSEcCtD
Imiquimod—Nausea—Everolimus—kidney cancer	0.000136	0.00033	CcSEcCtD
Imiquimod—Diarrhoea—Sorafenib—kidney cancer	0.000136	0.00033	CcSEcCtD
Imiquimod—Hypertension—Paclitaxel—kidney cancer	0.000136	0.000329	CcSEcCtD
Imiquimod—Pruritus—Sunitinib—kidney cancer	0.000136	0.000328	CcSEcCtD
Imiquimod—Angiopathy—Capecitabine—kidney cancer	0.000135	0.000326	CcSEcCtD
Imiquimod—Immune system disorder—Capecitabine—kidney cancer	0.000134	0.000325	CcSEcCtD
Imiquimod—Arthralgia—Paclitaxel—kidney cancer	0.000134	0.000325	CcSEcCtD
Imiquimod—Myalgia—Paclitaxel—kidney cancer	0.000134	0.000325	CcSEcCtD
Imiquimod—Chest pain—Paclitaxel—kidney cancer	0.000134	0.000325	CcSEcCtD
Imiquimod—Mediastinal disorder—Capecitabine—kidney cancer	0.000134	0.000324	CcSEcCtD
Imiquimod—Anxiety—Paclitaxel—kidney cancer	0.000134	0.000324	CcSEcCtD
Imiquimod—Face oedema—Doxorubicin—kidney cancer	0.000134	0.000323	CcSEcCtD
Imiquimod—Decreased appetite—Gemcitabine—kidney cancer	0.000134	0.000323	CcSEcCtD
Imiquimod—Hypersensitivity—Dactinomycin—kidney cancer	0.000134	0.000323	CcSEcCtD
Imiquimod—Chills—Capecitabine—kidney cancer	0.000134	0.000323	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000133	0.000323	CcSEcCtD
Imiquimod—Arrhythmia—Capecitabine—kidney cancer	0.000133	0.000321	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000133	0.000321	CcSEcCtD
Imiquimod—Discomfort—Paclitaxel—kidney cancer	0.000133	0.000321	CcSEcCtD
Imiquimod—Fatigue—Gemcitabine—kidney cancer	0.000133	0.000321	CcSEcCtD
Imiquimod—Gastrointestinal pain—Vincristine—kidney cancer	0.000133	0.000321	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—JUN—kidney cancer	0.000132	0.0011	CbGpPWpGaD
Imiquimod—Dizziness—Sorafenib—kidney cancer	0.000132	0.000318	CcSEcCtD
Imiquimod—Pain—Gemcitabine—kidney cancer	0.000132	0.000318	CcSEcCtD
Imiquimod—Nausea—Erlotinib—kidney cancer	0.000132	0.000318	CcSEcCtD
Imiquimod—Alopecia—Capecitabine—kidney cancer	0.000132	0.000318	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—CTNNB1—kidney cancer	0.000131	0.0011	CbGpPWpGaD
Imiquimod—Dry mouth—Paclitaxel—kidney cancer	0.000131	0.000318	CcSEcCtD
Imiquimod—Diarrhoea—Sunitinib—kidney cancer	0.000131	0.000317	CcSEcCtD
Imiquimod—Mental disorder—Capecitabine—kidney cancer	0.00013	0.000315	CcSEcCtD
Imiquimod—Asthenia—Dactinomycin—kidney cancer	0.00013	0.000315	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—KRAS—kidney cancer	0.00013	0.00108	CbGpPWpGaD
Imiquimod—Erythema—Capecitabine—kidney cancer	0.00013	0.000313	CcSEcCtD
Imiquimod—Malnutrition—Capecitabine—kidney cancer	0.00013	0.000313	CcSEcCtD
Imiquimod—Oedema—Paclitaxel—kidney cancer	0.000129	0.000311	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTP1—kidney cancer	0.000129	0.00107	CbGpPWpGaD
Imiquimod—Abdominal pain—Vincristine—kidney cancer	0.000128	0.00031	CcSEcCtD
Imiquimod—Body temperature increased—Vincristine—kidney cancer	0.000128	0.00031	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—PTEN—kidney cancer	0.000128	0.00107	CbGpPWpGaD
Imiquimod—Infection—Paclitaxel—kidney cancer	0.000128	0.000309	CcSEcCtD
Imiquimod—TLR7—Immune System—TSC2—kidney cancer	0.000128	0.00106	CbGpPWpGaD
Imiquimod—Dizziness—Sunitinib—kidney cancer	0.000127	0.000306	CcSEcCtD
Imiquimod—Feeling abnormal—Gemcitabine—kidney cancer	0.000127	0.000306	CcSEcCtD
Imiquimod—Shock—Paclitaxel—kidney cancer	0.000127	0.000306	CcSEcCtD
Imiquimod—Vomiting—Sorafenib—kidney cancer	0.000127	0.000306	CcSEcCtD
Imiquimod—Nervous system disorder—Paclitaxel—kidney cancer	0.000126	0.000305	CcSEcCtD
Imiquimod—Tachycardia—Paclitaxel—kidney cancer	0.000126	0.000304	CcSEcCtD
Imiquimod—Rash—Sorafenib—kidney cancer	0.000126	0.000304	CcSEcCtD
Imiquimod—Dermatitis—Sorafenib—kidney cancer	0.000126	0.000303	CcSEcCtD
Imiquimod—Back pain—Capecitabine—kidney cancer	0.000125	0.000303	CcSEcCtD
Imiquimod—Breast disorder—Doxorubicin—kidney cancer	0.000125	0.000303	CcSEcCtD
Imiquimod—Skin disorder—Paclitaxel—kidney cancer	0.000125	0.000302	CcSEcCtD
Imiquimod—Headache—Sorafenib—kidney cancer	0.000125	0.000302	CcSEcCtD
Imiquimod—Hyperhidrosis—Paclitaxel—kidney cancer	0.000125	0.000301	CcSEcCtD
Imiquimod—Diarrhoea—Dactinomycin—kidney cancer	0.000124	0.0003	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	0.000123	0.00103	CbGpPWpGaD
Imiquimod—Anorexia—Paclitaxel—kidney cancer	0.000123	0.000297	CcSEcCtD
Imiquimod—Vomiting—Sunitinib—kidney cancer	0.000122	0.000295	CcSEcCtD
Imiquimod—Body temperature increased—Gemcitabine—kidney cancer	0.000122	0.000294	CcSEcCtD
Imiquimod—Rash—Sunitinib—kidney cancer	0.000121	0.000292	CcSEcCtD
Imiquimod—Dermatitis—Sunitinib—kidney cancer	0.000121	0.000292	CcSEcCtD
Imiquimod—Ill-defined disorder—Capecitabine—kidney cancer	0.00012	0.00029	CcSEcCtD
Imiquimod—Headache—Sunitinib—kidney cancer	0.00012	0.00029	CcSEcCtD
Imiquimod—Influenza—Doxorubicin—kidney cancer	0.00012	0.00029	CcSEcCtD
Imiquimod—Hypersensitivity—Vincristine—kidney cancer	0.00012	0.000289	CcSEcCtD
Imiquimod—TLR8—Innate Immune System—PIK3CA—kidney cancer	0.000119	0.000994	CbGpPWpGaD
Imiquimod—Nausea—Sorafenib—kidney cancer	0.000118	0.000286	CcSEcCtD
Imiquimod—CYP1A2—Phase II conjugation—GSTM1—kidney cancer	0.000118	0.000985	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000117	0.000979	CbGpPWpGaD
Imiquimod—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000117	0.000284	CcSEcCtD
Imiquimod—Malaise—Capecitabine—kidney cancer	0.000117	0.000282	CcSEcCtD
Imiquimod—TLR8—Immune System—RAF1—kidney cancer	0.000117	0.000973	CbGpPWpGaD
Imiquimod—Insomnia—Paclitaxel—kidney cancer	0.000117	0.000282	CcSEcCtD
Imiquimod—Asthenia—Vincristine—kidney cancer	0.000116	0.000281	CcSEcCtD
Imiquimod—TLR8—Immune System—RELA—kidney cancer	0.000116	0.000968	CbGpPWpGaD
Imiquimod—Syncope—Capecitabine—kidney cancer	0.000116	0.000281	CcSEcCtD
Imiquimod—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000116	0.000966	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—kidney cancer	0.000116	0.000964	CbGpPWpGaD
Imiquimod—Paraesthesia—Paclitaxel—kidney cancer	0.000116	0.00028	CcSEcCtD
Imiquimod—TLR8—Immune System—ERBB2—kidney cancer	0.000115	0.000962	CbGpPWpGaD
Imiquimod—Vomiting—Dactinomycin—kidney cancer	0.000115	0.000279	CcSEcCtD
Imiquimod—Bronchitis—Doxorubicin—kidney cancer	0.000115	0.000279	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—RELA—kidney cancer	0.000115	0.00096	CbGpPWpGaD
Imiquimod—Dyspnoea—Paclitaxel—kidney cancer	0.000115	0.000278	CcSEcCtD
Imiquimod—Somnolence—Paclitaxel—kidney cancer	0.000115	0.000277	CcSEcCtD
Imiquimod—Palpitations—Capecitabine—kidney cancer	0.000114	0.000277	CcSEcCtD
Imiquimod—Rash—Dactinomycin—kidney cancer	0.000114	0.000277	CcSEcCtD
Imiquimod—TLR8—Immune System—MTOR—kidney cancer	0.000114	0.00095	CbGpPWpGaD
Imiquimod—Nausea—Sunitinib—kidney cancer	0.000114	0.000275	CcSEcCtD
Imiquimod—Loss of consciousness—Capecitabine—kidney cancer	0.000114	0.000275	CcSEcCtD
Imiquimod—Pancytopenia—Doxorubicin—kidney cancer	0.000114	0.000275	CcSEcCtD
Imiquimod—TLR8—Immune System—CD4—kidney cancer	0.000114	0.000948	CbGpPWpGaD
Imiquimod—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	0.000113	0.000946	CbGpPWpGaD
Imiquimod—Dyspepsia—Paclitaxel—kidney cancer	0.000113	0.000274	CcSEcCtD
Imiquimod—Cough—Capecitabine—kidney cancer	0.000113	0.000273	CcSEcCtD
Imiquimod—TLR7—Immune System—KIT—kidney cancer	0.000113	0.000939	CbGpPWpGaD
Imiquimod—Dysuria—Doxorubicin—kidney cancer	0.000112	0.000271	CcSEcCtD
Imiquimod—Decreased appetite—Paclitaxel—kidney cancer	0.000112	0.000271	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—kidney cancer	0.000112	0.000933	CbGpPWpGaD
Imiquimod—Hypertension—Capecitabine—kidney cancer	0.000112	0.00027	CcSEcCtD
Imiquimod—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000111	0.000269	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000111	0.000269	CcSEcCtD
Imiquimod—Fatigue—Paclitaxel—kidney cancer	0.000111	0.000268	CcSEcCtD
Imiquimod—Diarrhoea—Vincristine—kidney cancer	0.000111	0.000268	CcSEcCtD
Imiquimod—Asthenia—Gemcitabine—kidney cancer	0.00011	0.000267	CcSEcCtD
Imiquimod—Myalgia—Capecitabine—kidney cancer	0.00011	0.000266	CcSEcCtD
Imiquimod—Arthralgia—Capecitabine—kidney cancer	0.00011	0.000266	CcSEcCtD
Imiquimod—Chest pain—Capecitabine—kidney cancer	0.00011	0.000266	CcSEcCtD
Imiquimod—Pain—Paclitaxel—kidney cancer	0.00011	0.000266	CcSEcCtD
Imiquimod—Anxiety—Capecitabine—kidney cancer	0.00011	0.000266	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00011	0.000265	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—MAPK3—kidney cancer	0.000109	0.000912	CbGpPWpGaD
Imiquimod—Photosensitivity reaction—Doxorubicin—kidney cancer	0.000109	0.000264	CcSEcCtD
Imiquimod—Discomfort—Capecitabine—kidney cancer	0.000109	0.000263	CcSEcCtD
Imiquimod—Pruritus—Gemcitabine—kidney cancer	0.000109	0.000263	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTT1—kidney cancer	0.000109	0.000904	CbGpPWpGaD
Imiquimod—Dry mouth—Capecitabine—kidney cancer	0.000108	0.000261	CcSEcCtD
Imiquimod—Nausea—Dactinomycin—kidney cancer	0.000108	0.000261	CcSEcCtD
Imiquimod—Dizziness—Vincristine—kidney cancer	0.000107	0.000259	CcSEcCtD
Imiquimod—TLR8—Immune System—CDKN1B—kidney cancer	0.000107	0.000891	CbGpPWpGaD
Imiquimod—Infestation NOS—Doxorubicin—kidney cancer	0.000107	0.000258	CcSEcCtD
Imiquimod—Infestation—Doxorubicin—kidney cancer	0.000107	0.000258	CcSEcCtD
Imiquimod—Feeling abnormal—Paclitaxel—kidney cancer	0.000106	0.000257	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—kidney cancer	0.000106	0.000884	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—kidney cancer	0.000106	0.000884	CbGpPWpGaD
Imiquimod—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000106	0.000256	CcSEcCtD
Imiquimod—Oedema—Capecitabine—kidney cancer	0.000106	0.000255	CcSEcCtD
Imiquimod—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000105	0.000255	CcSEcCtD
Imiquimod—Diarrhoea—Gemcitabine—kidney cancer	0.000105	0.000254	CcSEcCtD
Imiquimod—Infection—Capecitabine—kidney cancer	0.000105	0.000254	CcSEcCtD
Imiquimod—Neuropathy peripheral—Doxorubicin—kidney cancer	0.000105	0.000253	CcSEcCtD
Imiquimod—CYP1A2—Arachidonic acid metabolism—PTGS2—kidney cancer	0.000105	0.000873	CbGpPWpGaD
Imiquimod—TLR8—Immune System—IL2—kidney cancer	0.000105	0.000872	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—MAPK1—kidney cancer	0.000104	0.000868	CbGpPWpGaD
Imiquimod—Shock—Capecitabine—kidney cancer	0.000104	0.000251	CcSEcCtD
Imiquimod—Conjunctivitis—Doxorubicin—kidney cancer	0.000104	0.000251	CcSEcCtD
Imiquimod—Urinary tract infection—Doxorubicin—kidney cancer	0.000104	0.000251	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—kidney cancer	0.000104	0.000865	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDH1—kidney cancer	0.000104	0.000864	CbGpPWpGaD
Imiquimod—Nervous system disorder—Capecitabine—kidney cancer	0.000104	0.000251	CcSEcCtD
Imiquimod—Tachycardia—Capecitabine—kidney cancer	0.000103	0.000249	CcSEcCtD
Imiquimod—Vomiting—Vincristine—kidney cancer	0.000103	0.000249	CcSEcCtD
Imiquimod—Skin disorder—Capecitabine—kidney cancer	0.000103	0.000248	CcSEcCtD
Imiquimod—Urticaria—Paclitaxel—kidney cancer	0.000102	0.000247	CcSEcCtD
Imiquimod—Rash—Vincristine—kidney cancer	0.000102	0.000247	CcSEcCtD
Imiquimod—Hyperhidrosis—Capecitabine—kidney cancer	0.000102	0.000247	CcSEcCtD
Imiquimod—Dermatitis—Vincristine—kidney cancer	0.000102	0.000247	CcSEcCtD
Imiquimod—Body temperature increased—Paclitaxel—kidney cancer	0.000102	0.000246	CcSEcCtD
Imiquimod—Abdominal pain—Paclitaxel—kidney cancer	0.000102	0.000246	CcSEcCtD
Imiquimod—TLR8—Immune System—JUN—kidney cancer	0.000102	0.000848	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—PTGS1—kidney cancer	0.000102	0.000848	CbGpPWpGaD
Imiquimod—Headache—Vincristine—kidney cancer	0.000102	0.000246	CcSEcCtD
Imiquimod—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000101	0.000244	CcSEcCtD
Imiquimod—TLR8—Immune System—CTNNB1—kidney cancer	0.000101	0.000842	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—kidney cancer	0.000101	0.000841	CbGpPWpGaD
Imiquimod—Anorexia—Capecitabine—kidney cancer	0.000101	0.000244	CcSEcCtD
Imiquimod—Sinusitis—Doxorubicin—kidney cancer	0.0001	0.000242	CcSEcCtD
Imiquimod—TLR8—Immune System—PTEN—kidney cancer	9.85e-05	0.000821	CbGpPWpGaD
Imiquimod—TLR7—Innate Immune System—KRAS—kidney cancer	9.84e-05	0.00082	CbGpPWpGaD
Imiquimod—Vomiting—Gemcitabine—kidney cancer	9.78e-05	0.000236	CcSEcCtD
Imiquimod—Rash—Gemcitabine—kidney cancer	9.7e-05	0.000234	CcSEcCtD
Imiquimod—Dermatitis—Gemcitabine—kidney cancer	9.69e-05	0.000234	CcSEcCtD
Imiquimod—Haemoglobin—Doxorubicin—kidney cancer	9.64e-05	0.000233	CcSEcCtD
Imiquimod—Headache—Gemcitabine—kidney cancer	9.64e-05	0.000233	CcSEcCtD
Imiquimod—Nausea—Vincristine—kidney cancer	9.63e-05	0.000233	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Capecitabine—kidney cancer	9.63e-05	0.000233	CcSEcCtD
Imiquimod—Rhinitis—Doxorubicin—kidney cancer	9.62e-05	0.000232	CcSEcCtD
Imiquimod—Haemorrhage—Doxorubicin—kidney cancer	9.59e-05	0.000232	CcSEcCtD
Imiquimod—Insomnia—Capecitabine—kidney cancer	9.56e-05	0.000231	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	9.52e-05	0.000794	CbGpPWpGaD
Imiquimod—Pharyngitis—Doxorubicin—kidney cancer	9.52e-05	0.00023	CcSEcCtD
Imiquimod—Paraesthesia—Capecitabine—kidney cancer	9.49e-05	0.000229	CcSEcCtD
Imiquimod—Hypersensitivity—Paclitaxel—kidney cancer	9.49e-05	0.000229	CcSEcCtD
Imiquimod—Urinary tract disorder—Doxorubicin—kidney cancer	9.47e-05	0.000229	CcSEcCtD
Imiquimod—Connective tissue disorder—Doxorubicin—kidney cancer	9.43e-05	0.000228	CcSEcCtD
Imiquimod—Dyspnoea—Capecitabine—kidney cancer	9.43e-05	0.000228	CcSEcCtD
Imiquimod—Urethral disorder—Doxorubicin—kidney cancer	9.4e-05	0.000227	CcSEcCtD
Imiquimod—Dyspepsia—Capecitabine—kidney cancer	9.31e-05	0.000225	CcSEcCtD
Imiquimod—Visual impairment—Doxorubicin—kidney cancer	9.24e-05	0.000223	CcSEcCtD
Imiquimod—Asthenia—Paclitaxel—kidney cancer	9.24e-05	0.000223	CcSEcCtD
Imiquimod—CYP1A2—Phase 1 - Functionalization of compounds—POMC—kidney cancer	9.2e-05	0.000767	CbGpPWpGaD
Imiquimod—Decreased appetite—Capecitabine—kidney cancer	9.19e-05	0.000222	CcSEcCtD
Imiquimod—Nausea—Gemcitabine—kidney cancer	9.14e-05	0.000221	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Capecitabine—kidney cancer	9.13e-05	0.000221	CcSEcCtD
Imiquimod—Fatigue—Capecitabine—kidney cancer	9.12e-05	0.00022	CcSEcCtD
Imiquimod—Pruritus—Paclitaxel—kidney cancer	9.11e-05	0.00022	CcSEcCtD
Imiquimod—Erythema multiforme—Doxorubicin—kidney cancer	9.07e-05	0.000219	CcSEcCtD
Imiquimod—Pain—Capecitabine—kidney cancer	9.04e-05	0.000218	CcSEcCtD
Imiquimod—TLR7—Innate Immune System—PIK3CA—kidney cancer	9.04e-05	0.000753	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—GLIPR1—kidney cancer	8.97e-05	0.000748	CbGpPWpGaD
Imiquimod—Eye disorder—Doxorubicin—kidney cancer	8.96e-05	0.000217	CcSEcCtD
Imiquimod—Tinnitus—Doxorubicin—kidney cancer	8.94e-05	0.000216	CcSEcCtD
Imiquimod—Flushing—Doxorubicin—kidney cancer	8.9e-05	0.000215	CcSEcCtD
Imiquimod—TLR7—Immune System—RAF1—kidney cancer	8.85e-05	0.000737	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—kidney cancer	8.82e-05	0.000735	CbGpPWpGaD
Imiquimod—Diarrhoea—Paclitaxel—kidney cancer	8.81e-05	0.000213	CcSEcCtD
Imiquimod—TLR7—Immune System—RELA—kidney cancer	8.81e-05	0.000734	CbGpPWpGaD
Imiquimod—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.76e-05	0.00073	CbGpPWpGaD
Imiquimod—TLR7—Immune System—ERBB2—kidney cancer	8.75e-05	0.000729	CbGpPWpGaD
Imiquimod—Feeling abnormal—Capecitabine—kidney cancer	8.71e-05	0.000211	CcSEcCtD
Imiquimod—Angiopathy—Doxorubicin—kidney cancer	8.7e-05	0.00021	CcSEcCtD
Imiquimod—Immune system disorder—Doxorubicin—kidney cancer	8.66e-05	0.000209	CcSEcCtD
Imiquimod—Gastrointestinal pain—Capecitabine—kidney cancer	8.65e-05	0.000209	CcSEcCtD
Imiquimod—Mediastinal disorder—Doxorubicin—kidney cancer	8.65e-05	0.000209	CcSEcCtD
Imiquimod—TLR7—Immune System—MTOR—kidney cancer	8.64e-05	0.00072	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CD4—kidney cancer	8.62e-05	0.000718	CbGpPWpGaD
Imiquimod—Chills—Doxorubicin—kidney cancer	8.61e-05	0.000208	CcSEcCtD
Imiquimod—Arrhythmia—Doxorubicin—kidney cancer	8.57e-05	0.000207	CcSEcCtD
Imiquimod—Dizziness—Paclitaxel—kidney cancer	8.52e-05	0.000206	CcSEcCtD
Imiquimod—Alopecia—Doxorubicin—kidney cancer	8.48e-05	0.000205	CcSEcCtD
Imiquimod—TLR8—Immune System—MAPK3—kidney cancer	8.41e-05	0.000701	CbGpPWpGaD
Imiquimod—Mental disorder—Doxorubicin—kidney cancer	8.4e-05	0.000203	CcSEcCtD
Imiquimod—Urticaria—Capecitabine—kidney cancer	8.4e-05	0.000203	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTT1—kidney cancer	8.38e-05	0.000698	CbGpPWpGaD
Imiquimod—Abdominal pain—Capecitabine—kidney cancer	8.36e-05	0.000202	CcSEcCtD
Imiquimod—Body temperature increased—Capecitabine—kidney cancer	8.36e-05	0.000202	CcSEcCtD
Imiquimod—Malnutrition—Doxorubicin—kidney cancer	8.35e-05	0.000202	CcSEcCtD
Imiquimod—Erythema—Doxorubicin—kidney cancer	8.35e-05	0.000202	CcSEcCtD
Imiquimod—Vomiting—Paclitaxel—kidney cancer	8.19e-05	0.000198	CcSEcCtD
Imiquimod—Rash—Paclitaxel—kidney cancer	8.12e-05	0.000196	CcSEcCtD
Imiquimod—Dermatitis—Paclitaxel—kidney cancer	8.12e-05	0.000196	CcSEcCtD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MYC—kidney cancer	8.11e-05	0.000676	CbGpPWpGaD
Imiquimod—TLR7—Immune System—CDKN1B—kidney cancer	8.11e-05	0.000675	CbGpPWpGaD
Imiquimod—Back pain—Doxorubicin—kidney cancer	8.08e-05	0.000195	CcSEcCtD
Imiquimod—Headache—Paclitaxel—kidney cancer	8.07e-05	0.000195	CcSEcCtD
Imiquimod—TLR8—Immune System—MAPK1—kidney cancer	8.01e-05	0.000667	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—kidney cancer	7.94e-05	0.000661	CbGpPWpGaD
Imiquimod—TLR7—Immune System—IL2—kidney cancer	7.93e-05	0.000661	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—PTGS1—kidney cancer	7.85e-05	0.000654	CbGpPWpGaD
Imiquimod—Hypersensitivity—Capecitabine—kidney cancer	7.79e-05	0.000188	CcSEcCtD
Imiquimod—Ill-defined disorder—Doxorubicin—kidney cancer	7.75e-05	0.000187	CcSEcCtD
Imiquimod—TLR7—Immune System—JUN—kidney cancer	7.72e-05	0.000643	CbGpPWpGaD
Imiquimod—Agitation—Doxorubicin—kidney cancer	7.67e-05	0.000185	CcSEcCtD
Imiquimod—TLR7—Immune System—CTNNB1—kidney cancer	7.66e-05	0.000638	CbGpPWpGaD
Imiquimod—Nausea—Paclitaxel—kidney cancer	7.65e-05	0.000185	CcSEcCtD
Imiquimod—Asthenia—Capecitabine—kidney cancer	7.59e-05	0.000183	CcSEcCtD
Imiquimod—TLR8—Immune System—KRAS—kidney cancer	7.56e-05	0.00063	CbGpPWpGaD
Imiquimod—Malaise—Doxorubicin—kidney cancer	7.53e-05	0.000182	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—GSTP1—kidney cancer	7.52e-05	0.000627	CbGpPWpGaD
Imiquimod—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—kidney cancer	7.5e-05	0.000625	CbGpPWpGaD
Imiquimod—Syncope—Doxorubicin—kidney cancer	7.49e-05	0.000181	CcSEcCtD
Imiquimod—Pruritus—Capecitabine—kidney cancer	7.48e-05	0.000181	CcSEcCtD
Imiquimod—TLR7—Immune System—PTEN—kidney cancer	7.46e-05	0.000622	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTP1—kidney cancer	7.42e-05	0.000618	CbGpPWpGaD
Imiquimod—Palpitations—Doxorubicin—kidney cancer	7.38e-05	0.000178	CcSEcCtD
Imiquimod—Loss of consciousness—Doxorubicin—kidney cancer	7.34e-05	0.000177	CcSEcCtD
Imiquimod—Cough—Doxorubicin—kidney cancer	7.29e-05	0.000176	CcSEcCtD
Imiquimod—Convulsion—Doxorubicin—kidney cancer	7.24e-05	0.000175	CcSEcCtD
Imiquimod—Diarrhoea—Capecitabine—kidney cancer	7.23e-05	0.000175	CcSEcCtD
Imiquimod—Hypertension—Doxorubicin—kidney cancer	7.21e-05	0.000174	CcSEcCtD
Imiquimod—Arthralgia—Doxorubicin—kidney cancer	7.11e-05	0.000172	CcSEcCtD
Imiquimod—Myalgia—Doxorubicin—kidney cancer	7.11e-05	0.000172	CcSEcCtD
Imiquimod—Chest pain—Doxorubicin—kidney cancer	7.11e-05	0.000172	CcSEcCtD
Imiquimod—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	7.1e-05	0.000592	CbGpPWpGaD
Imiquimod—Anxiety—Doxorubicin—kidney cancer	7.08e-05	0.000171	CcSEcCtD
Imiquimod—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	7.06e-05	0.000171	CcSEcCtD
Imiquimod—Discomfort—Doxorubicin—kidney cancer	7.02e-05	0.00017	CcSEcCtD
Imiquimod—Dizziness—Capecitabine—kidney cancer	6.99e-05	0.000169	CcSEcCtD
Imiquimod—Dry mouth—Doxorubicin—kidney cancer	6.95e-05	0.000168	CcSEcCtD
Imiquimod—TLR8—Immune System—PIK3CA—kidney cancer	6.95e-05	0.000579	CbGpPWpGaD
Imiquimod—CYP1A2—Biological oxidations—GSTM1—kidney cancer	6.91e-05	0.000576	CbGpPWpGaD
Imiquimod—CYP1A2—Metapathway biotransformation—GSTM1—kidney cancer	6.82e-05	0.000568	CbGpPWpGaD
Imiquimod—Oedema—Doxorubicin—kidney cancer	6.82e-05	0.000165	CcSEcCtD
Imiquimod—Infection—Doxorubicin—kidney cancer	6.77e-05	0.000164	CcSEcCtD
Imiquimod—Vomiting—Capecitabine—kidney cancer	6.72e-05	0.000162	CcSEcCtD
Imiquimod—Shock—Doxorubicin—kidney cancer	6.71e-05	0.000162	CcSEcCtD
Imiquimod—Nervous system disorder—Doxorubicin—kidney cancer	6.68e-05	0.000161	CcSEcCtD
Imiquimod—Rash—Capecitabine—kidney cancer	6.67e-05	0.000161	CcSEcCtD
Imiquimod—Dermatitis—Capecitabine—kidney cancer	6.66e-05	0.000161	CcSEcCtD
Imiquimod—Tachycardia—Doxorubicin—kidney cancer	6.65e-05	0.000161	CcSEcCtD
Imiquimod—Headache—Capecitabine—kidney cancer	6.62e-05	0.00016	CcSEcCtD
Imiquimod—Skin disorder—Doxorubicin—kidney cancer	6.62e-05	0.00016	CcSEcCtD
Imiquimod—Hyperhidrosis—Doxorubicin—kidney cancer	6.59e-05	0.000159	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—CYP1A1—kidney cancer	6.55e-05	0.000546	CbGpPWpGaD
Imiquimod—Anorexia—Doxorubicin—kidney cancer	6.5e-05	0.000157	CcSEcCtD
Imiquimod—CYP1A2—Metapathway biotransformation—CYP1A1—kidney cancer	6.46e-05	0.000539	CbGpPWpGaD
Imiquimod—TLR7—Immune System—MAPK3—kidney cancer	6.38e-05	0.000531	CbGpPWpGaD
Imiquimod—Nausea—Capecitabine—kidney cancer	6.28e-05	0.000152	CcSEcCtD
Imiquimod—Musculoskeletal discomfort—Doxorubicin—kidney cancer	6.21e-05	0.00015	CcSEcCtD
Imiquimod—Insomnia—Doxorubicin—kidney cancer	6.16e-05	0.000149	CcSEcCtD
Imiquimod—Paraesthesia—Doxorubicin—kidney cancer	6.12e-05	0.000148	CcSEcCtD
Imiquimod—Dyspnoea—Doxorubicin—kidney cancer	6.08e-05	0.000147	CcSEcCtD
Imiquimod—TLR7—Immune System—MAPK1—kidney cancer	6.07e-05	0.000506	CbGpPWpGaD
Imiquimod—Somnolence—Doxorubicin—kidney cancer	6.06e-05	0.000146	CcSEcCtD
Imiquimod—Dyspepsia—Doxorubicin—kidney cancer	6e-05	0.000145	CcSEcCtD
Imiquimod—Decreased appetite—Doxorubicin—kidney cancer	5.92e-05	0.000143	CcSEcCtD
Imiquimod—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.88e-05	0.000142	CcSEcCtD
Imiquimod—Fatigue—Doxorubicin—kidney cancer	5.88e-05	0.000142	CcSEcCtD
Imiquimod—Pain—Doxorubicin—kidney cancer	5.83e-05	0.000141	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTP1—kidney cancer	5.81e-05	0.000484	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ACY1—kidney cancer	5.76e-05	0.00048	CbGpPWpGaD
Imiquimod—TLR7—Immune System—KRAS—kidney cancer	5.73e-05	0.000478	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	5.73e-05	0.000477	CbGpPWpGaD
Imiquimod—Feeling abnormal—Doxorubicin—kidney cancer	5.62e-05	0.000136	CcSEcCtD
Imiquimod—Gastrointestinal pain—Doxorubicin—kidney cancer	5.57e-05	0.000135	CcSEcCtD
Imiquimod—Urticaria—Doxorubicin—kidney cancer	5.41e-05	0.000131	CcSEcCtD
Imiquimod—Body temperature increased—Doxorubicin—kidney cancer	5.39e-05	0.00013	CcSEcCtD
Imiquimod—Abdominal pain—Doxorubicin—kidney cancer	5.39e-05	0.00013	CcSEcCtD
Imiquimod—CYP3A4—Biological oxidations—GSTM1—kidney cancer	5.34e-05	0.000445	CbGpPWpGaD
Imiquimod—TLR7—Immune System—PIK3CA—kidney cancer	5.26e-05	0.000439	CbGpPWpGaD
Imiquimod—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	5.26e-05	0.000439	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	5.06e-05	0.000422	CbGpPWpGaD
Imiquimod—Hypersensitivity—Doxorubicin—kidney cancer	5.02e-05	0.000121	CcSEcCtD
Imiquimod—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	4.99e-05	0.000416	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	4.92e-05	0.00041	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PDHB—kidney cancer	4.9e-05	0.000408	CbGpPWpGaD
Imiquimod—Asthenia—Doxorubicin—kidney cancer	4.89e-05	0.000118	CcSEcCtD
Imiquimod—CYP1A2—Biological oxidations—POMC—kidney cancer	4.89e-05	0.000407	CbGpPWpGaD
Imiquimod—Pruritus—Doxorubicin—kidney cancer	4.82e-05	0.000117	CcSEcCtD
Imiquimod—Diarrhoea—Doxorubicin—kidney cancer	4.66e-05	0.000113	CcSEcCtD
Imiquimod—CYP1A2—Metabolism—CCBL1—kidney cancer	4.61e-05	0.000384	CbGpPWpGaD
Imiquimod—Dizziness—Doxorubicin—kidney cancer	4.51e-05	0.000109	CcSEcCtD
Imiquimod—CYP3A4—Metabolism—ACY1—kidney cancer	4.45e-05	0.000371	CbGpPWpGaD
Imiquimod—Vomiting—Doxorubicin—kidney cancer	4.33e-05	0.000105	CcSEcCtD
Imiquimod—Rash—Doxorubicin—kidney cancer	4.3e-05	0.000104	CcSEcCtD
Imiquimod—Dermatitis—Doxorubicin—kidney cancer	4.29e-05	0.000104	CcSEcCtD
Imiquimod—Headache—Doxorubicin—kidney cancer	4.27e-05	0.000103	CcSEcCtD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	4.17e-05	0.000347	CbGpPWpGaD
Imiquimod—Nausea—Doxorubicin—kidney cancer	4.05e-05	9.78e-05	CcSEcCtD
Imiquimod—CYP1A2—Metabolism—GLIPR1—kidney cancer	4e-05	0.000333	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PPAT—kidney cancer	4e-05	0.000333	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	3.95e-05	0.000329	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	3.91e-05	0.000325	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PDHB—kidney cancer	3.78e-05	0.000315	CbGpPWpGaD
Imiquimod—CYP3A4—Biological oxidations—POMC—kidney cancer	3.77e-05	0.000314	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—APRT—kidney cancer	3.71e-05	0.00031	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—FH—kidney cancer	3.71e-05	0.00031	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	3.63e-05	0.000303	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CCBL1—kidney cancer	3.56e-05	0.000296	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GPC3—kidney cancer	3.49e-05	0.000291	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CA2—kidney cancer	3.4e-05	0.000283	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALAD—kidney cancer	3.31e-05	0.000276	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ST3GAL2—kidney cancer	3.23e-05	0.000269	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ALDH1A1—kidney cancer	3.16e-05	0.000263	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.08e-05	0.000257	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PPAT—kidney cancer	3.08e-05	0.000257	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC5A3—kidney cancer	3.03e-05	0.000252	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PGK1—kidney cancer	3.03e-05	0.000252	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—LDHB—kidney cancer	2.97e-05	0.000247	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—APRT—kidney cancer	2.87e-05	0.000239	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—FH—kidney cancer	2.87e-05	0.000239	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GPC3—kidney cancer	2.7e-05	0.000225	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CA2—kidney cancer	2.62e-05	0.000219	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CA9—kidney cancer	2.57e-05	0.000215	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALAD—kidney cancer	2.56e-05	0.000213	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	2.52e-05	0.00021	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.49e-05	0.000208	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.44e-05	0.000203	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.34e-05	0.000195	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PGK1—kidney cancer	2.34e-05	0.000195	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—LDHB—kidney cancer	2.29e-05	0.000191	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CRABP1—kidney cancer	2.19e-05	0.000182	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ITPR2—kidney cancer	2.04e-05	0.00017	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CA9—kidney cancer	1.99e-05	0.000166	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.88e-05	0.000156	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTT1—kidney cancer	1.86e-05	0.000155	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ACHE—kidney cancer	1.86e-05	0.000155	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SCARB1—kidney cancer	1.76e-05	0.000146	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS1—kidney cancer	1.74e-05	0.000145	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PSMD7—kidney cancer	1.71e-05	0.000142	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CRABP1—kidney cancer	1.69e-05	0.000141	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—BCHE—kidney cancer	1.62e-05	0.000135	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC5A5—kidney cancer	1.6e-05	0.000133	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ITPR2—kidney cancer	1.57e-05	0.000131	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—SLC2A1—kidney cancer	1.54e-05	0.000129	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	1.5e-05	0.000125	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ACHE—kidney cancer	1.43e-05	0.000119	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTT1—kidney cancer	1.43e-05	0.000119	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SCARB1—kidney cancer	1.36e-05	0.000113	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS1—kidney cancer	1.34e-05	0.000112	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PSMD7—kidney cancer	1.32e-05	0.00011	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	1.31e-05	0.000109	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTP1—kidney cancer	1.29e-05	0.000107	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—BCHE—kidney cancer	1.25e-05	0.000104	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.23e-05	0.000103	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—ABCB1—kidney cancer	1.22e-05	0.000101	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.19e-05	9.92e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—GSTM1—kidney cancer	1.18e-05	9.85e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—CYP1A1—kidney cancer	1.12e-05	9.34e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTP1—kidney cancer	9.93e-06	8.27e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—ABCB1—kidney cancer	9.4e-06	7.83e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	9.21e-06	7.67e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—GSTM1—kidney cancer	9.12e-06	7.6e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—CYP1A1—kidney cancer	8.65e-06	7.21e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—POMC—kidney cancer	8.36e-06	6.96e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTGS2—kidney cancer	6.67e-06	5.55e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—POMC—kidney cancer	6.45e-06	5.37e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PTEN—kidney cancer	5.81e-06	4.84e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTGS2—kidney cancer	5.14e-06	4.29e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PTEN—kidney cancer	4.49e-06	3.74e-05	CbGpPWpGaD
Imiquimod—CYP1A2—Metabolism—PIK3CA—kidney cancer	4.1e-06	3.42e-05	CbGpPWpGaD
Imiquimod—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.16e-06	2.64e-05	CbGpPWpGaD
